Compile Data Set for Download or QSAR
Report error Found 22 Enz. Inhib. hit(s) with all data for entry = 610
TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281763(9-(2-acryloyl-1,2,3,4- tetrahydroisoquinolin- 5-yl...)
Affinity DataIC50: 0.000300nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281762(4-(2-acryloyl-1,2,3,4- tetrahydroisoquinolin- 5-yl...)
Affinity DataIC50: 0.000300nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281761(4-(2-acryloyl-1,2,3,4- tetrahydroisoquinolin- 5-yl...)
Affinity DataIC50: 0.000260nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281764(5-(2-acryloyl-1,2,3,4- tetrahydroisoquinolin- 5-yl...)
Affinity DataIC50: 0.000600nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281758(4-(2-acryloyl-1,2,3,4- tetrahydroisoquinolin- 5-yl...)
Affinity DataIC50: 0.0290nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281750(5-(2-Acryloyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-...)
Affinity DataIC50: 0.0450nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281746(4-(2-Acryloyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-...)
Affinity DataIC50: 0.0670nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281754(US10023534, Example 13 | US10023534, Example 14)
Affinity DataIC50: 0.0730nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281745(US10023534, Example 3 | US10023534, Example 8)
Affinity DataIC50: 0.0750nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281745(US10023534, Example 3 | US10023534, Example 8)
Affinity DataIC50: 0.0770nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281744(US10023534, Example 1 | (RS)-5-(2-Acryloyl-1,2,3,4...)
Affinity DataIC50: 0.120nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281754(US10023534, Example 13 | US10023534, Example 14)
Affinity DataIC50: 0.130nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281751(US10023534, Example 10 | 5-(2-Acryloyl-1,2,3,4-tet...)
Affinity DataIC50: 0.130nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281760(4-(2-acryloyl-1,2,3,4- tetrahydroisoquinolin- 5-yl...)
Affinity DataIC50: 0.170nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281756(4-(2-Acryloyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-...)
Affinity DataIC50: 0.180nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281748(4-(2-Acryloyl-1,2,3,4-tetrahydroisoquinolin-5-yl)-...)
Affinity DataIC50: 0.180nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281744(US10023534, Example 1 | (RS)-5-(2-Acryloyl-1,2,3,4...)
Affinity DataIC50: 0.180nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281751(US10023534, Example 10 | 5-(2-Acryloyl-1,2,3,4-tet...)
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281753(4-(5-Acryloyl-2,3,4,5-tetrahydrobenzo[b][1,4]oxaze...)
Affinity DataIC50: 0.370nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281757(4-(2-acryloyl-1,2,3,4- tetrahydroisoquinolin- 5-yl...)
Affinity DataIC50: 1.5nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281765(9-(2-acryloyl-1,2,3,4- tetrahydroisoquinolin- 5-yl...)
Affinity DataIC50: 2.30nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM281759(4-(2-cyano-1,2,3,4- tetrahydroisoquinolin- 5-yl)-3...)
Affinity DataIC50: 4.80nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
Go to US Patent